Received Jun 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | H97H2 | — |
second dose was given April 8, 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 77-year-old female patient who received Herpes zoster (Shingrix) (batch number H97H2, expiry date 29-MAR-2027) for prophylaxis. Previously administered products included Shingrix (a patient received a first dose of Shingrix back in September 21, 2018). On 08-APR-2025, the patient received the 2nd dose of Shingrix. On 08-APR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: second dose was given April 8, 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 10-JUN-2025 Pharmacist called on June 10, 2025 to report a patient received a first dose of Shingrix back in September 21, 2018 and then a second dose was given April 8, 2025. The Vaccine Administration Facility was the same as Primary Reporter. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule. This case was linked with US2025072148, reported by same reporter different patient.; Sender's Comments: US-GSK-US2025072148:case created for husband and wife